Bioglan and Stada partner to increase capacity to meet rising demand for Parkinson’s treatment

  • REIG JOFRE’s Bioglan subsidiary in Sweden and STADA are investing EUR3 million to expand Bioglan’s facilities with a highly technological production line devoted to a patented combination therapy for Parkinson’s disease
  • Bioglan is the exclusive manufacturer for the European market of the medicine, which is marketed by STADA as a treatment indicated for advanced Parkinson’s disease
  • The therapy has already been approved in several European countries and is currently marketed by STADA in Nordic countries, Germany, Austria, and Slovenia, with further launches imminent

Download the full document (PDF)